Exclusive: FDA probing death of Aduhelm patient as Biogen's Alzheimer's drug continues to stir controversy
The FDA tells Endpoints News today that it’s aware of the death of a patient taking Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) and is “actively investigating” the case.
Their statement follows the latest comments from RBC analyst Brian Abrahams, who is back with an update on the death, and this time he says that there are solid reasons to believe that the event was likely drug related and may have been preventable.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.